Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 1;2(2):202-210.
doi: 10.1007/s40472-015-0059-4.

New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases

Jennifer R Ferrer  1 , Attasit Chokechanachaisakul  2 , Jason A Wertheim  3
Affiliations

New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases

Jennifer R Ferrer et al. Curr Transplant Rep. .

Abstract

The current standard of care for end stage liver disease is orthotopic liver transplantation (OLT). Through improvement in surgical techniques, immunosuppression, and general medical care, liver transplantation has become an effective treatment over the course of the last half-century. Unfortunately, due to the limited availability of donor organs, there is a finite limit to the number of patients who will benefit from this therapy. This review will discuss current research in experimental cellular therapies for acute, chronic, and metabolic liver failure that may be appropriate when liver transplantation is not an immediate option.

Keywords: Alternative cell sources; Cellular therapy; Hepatocyte transplantation; Stem cells.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Jennifer R. Ferrer and Attasit Chokechanachaisakul declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Description of cell sources that have been investigated for use in hepatocyte transplantation
Fig. 2
Fig. 2
Isolation of primary human hepatocytes and implantation into a FAH −/− recipient allows for repopulation and restoration of liver function. (Reproduced with permission from [65]
See this image and copyright information in PMC

References

    1. Ito M, Nagata G, Miyakawa S, Fox IJ. Review of hepatocyte transplantation. J Hepatobiliary Pancreatic Surg. 2009;6(2):97–100. - PubMed
    1. Fox IJ, Roy-Chowdhury J. Hepatocyte transplantation. J Hepatol. 2004;40(6):878–86. - PubMed
    1. Nussler AK, Zeilinger K, Schyschka L, et al. Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues. J Mater Sci Mater Med. 2011;22:1087–99. - PubMed
    1. Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med. 1998;338(20):1422–6. - PubMed
    1. Baccarani U, Adani GL, Sanna A, et al. Portal vein thrombosis after intraportal hepatocytes transplantation in a liver transplant recipient. Transpl Intl. 2005;18(6):750–4. - PubMed

LinkOut - more resources